Specify a stock or a cryptocurrency in the search bar to get a summary
Phio Pharmaceuticals Corp
PHIOPhio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts. Address: 11 Apex Drive, Marlborough, MA, United States, 01752
Analytics
WallStreet Target Price
36 USDP/E ratio
0.0119Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures PHIO
Dividend Analytics PHIO
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History PHIO
Stock Valuation PHIO
Financials PHIO
Results | 2019 | Dynamics |